يعرض 1 - 20 نتائج من 1,204 نتيجة بحث عن '"SIMULTANEOUS INTEGRATED BOOST"', وقت الاستعلام: 0.87s تنقيح النتائج
  1. 1
  2. 2
  3. 3
  4. 4
    Academic Journal
  5. 5
    Academic Journal
  6. 6
    Academic Journal
  7. 7
    Academic Journal
  8. 8
    Academic Journal
  9. 9
    Academic Journal
  10. 10
    Academic Journal

    المصدر: Cancer Urology; Том 20, № 1 (2024); 60-66 ; Онкоурология; Том 20, № 1 (2024); 60-66 ; 1996-1812 ; 1726-9776

    وصف الملف: application/pdf

    Relation: https://oncourology.abvpress.ru/oncur/article/view/1733/1520; Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. 252 с.; Крашенинников А.А., Алексеев Б.Я., Нюшко К.М. и др. Лечение больных раком предстательной железы высокого риска прогрессирования. Онкология. Журнал им. П.А. Герцена 2019;8(6):460–5. DOI:10.17116/onkolog20198061460; National Comprehensive Cancer Network. Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.; Dearnaley D.P., Jovic G., Syndikus I. et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol 2014;15(4):464–73. DOI:10.1016/S1470-2045(14)70040-3; Peeters S.T., Heemsbergen W.D., Koper P.C. et al. Dose-response in radiotherapy for localized prostate cancer: results of the dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;24(13):1990–6. DOI:10.1200/JCO.2005.05.2530; Murthy V., Maitre P., Kannan S. et al. Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial. J Clin Oncol 2021;39(11):1234–42. DOI:10.1200/JCO.20.03282; Hennequin C., Sargos P., Roca L. et al. Long-term results of dose escalation (80 vs 70 Gy) combined with long-term androgen deprivation in high-risk prostate cancers: GETUG-AFU 18 randomized trial. J Clin Oncol 2024;42(4_suppl). DOI:10.1200/JCO.2024.42.4_suppl.LBA259; https://oncourology.abvpress.ru/oncur/article/view/1733

  11. 11
    Academic Journal

    المصدر: Creative surgery and oncology; Том 14, № 2 (2024); 153-157 ; Креативная хирургия и онкология; Том 14, № 2 (2024); 153-157 ; 2076-3093 ; 2307-0501

    وصف الملف: application/pdf

    Relation: https://www.surgonco.ru/jour/article/view/951/602; Яковленко Ю.Г. Глиобластомы: современное состояние проблемы. Медицинский вестник Юга России. 2019;10(4):28–35. DOI:10.21886/2219-8075-2019-10-4-28-35; Ostrom Q.T., Gittleman H., Truitt G., Boscia A., Kruchko C., Barnholtz-Sloan J.S. CBTRUS Statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. NeuroOncol. 2018;20(1):81–6. DOI:10.1093/neuonc/noy131; Wang J.Z., Li X.A. Impact of tumor repopulation on radiotherapy planning. Int J Radiat Oncol Biol Phys. 2005;61(1):220–7. DOI:10.1016/j.ijrobp.2004.09.043; Piroth M.D., Pinkawa M., Holy R., Stoffels G., Demirel C., Attieh C., et al. Integrated-boost IMRT or 3-D-CRT using FET-PET based autocontoured target volume delineation for glioblastoma multiforme — a dosimetric comparison. Radiation Oncology. 2019;4(2):57–9. DOI:10.1186/1748-717X-4-57; Zhong L., Chen L., Shengqing L. Efficacy of moderately hypofractionated simultaneous integrated boost intensitymodulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience. Radiation Oncology. 2019;14(1):104–8. DOI:10.1186/s13014-019-1305-1; Cao J.Q., Fisher B.J., Bauman G.S., Megyesi J.F., Watling C.J., Macdonald D.R. Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience. J Neurooncol. 2012;107(2):395–405. DOI:10.1007/s11060-011-0766-3; Gregucci F., Bonaparte I., Laera L., Ciliberti M.P., Carbonara R., Gentile M.A., et al. Poor-prognosis patients affected by glioblastoma: retrospective study of hypofractionated radiotherapy with simultaneous integrated boost and concurrent/adjuvant temozolomide. J Pers Med. 2021;11(2):1145–52. DOI:10.3390/jpm11111145; El-Ghany Khedr R.A., Sheta M.F., Elmorsy W. The outcomes of concomitant hypofractionated simultaneous integrated boost intensitymodulated radiotherapy with temozolomide for newly diagnosed high-grade gliomas. Oncol Radiother. 2015;12(1):20–9.; Shenouda G., Souhami L., Petrecca K., Owen S., Panet-Raymond V., Guiot M.C., et al. A phase 2 trial of neoadjuvant temozolomide followed by hypofractionated accelerated radiation therapy with concurrent and adjuvant temozolomide for patients with glioblastoma. Int J Radiat Oncol Biol Phys. 2017;97(3):487–94. DOI:10.1016/j.ijrobp.2016.11.006; Nie E., Miao F., Jin X., Wu W., Zhou X., Zeng A., et al. Fstl1/DIP2A/ MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma. Oncogene. 2019;38(15):2706–21. DOI:10.1038/s41388-018-0596-2; Dobelbower M.C., Burnet Iii O.L., Nordal R.A., Nabors L.B., Markert J.M., Hyatt M.D., et al. Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide. J Med Imaging Radiat Oncol. 2011;55(1):77–81. DOI:10.1111/j.1754-9485.2010.02232.x; Minniti G., Amelio D., Amichetti M., Salvati M., Muni R., Bozzao A., et al. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother Oncol. 2010;97(3):377–81. DOI:10.1016/j.radonc.2010.08.020; Mallick S., Kunhiparambath H., Gupta S., Benson R., Sharma S., Laviraj M.A., et al. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial). J Neuro-Oncol. 2018;140(1):75–82. DOI:10.1007/s11060-018-2932-3; Scoccianti S., Krengli M., Marrazzo L., Magrini S.M., Detti B., Fusco V., et al. Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the brain study Group of the Italian Association of radiation oncology (AIRO). Radiol Med. 2018;123(1):48–62. DOI:10.1007/s11547-017-0806-y; https://www.surgonco.ru/jour/article/view/951

  12. 12
    Academic Journal
  13. 13
    Academic Journal
  14. 14
    Academic Journal
  15. 15
  16. 16
    Academic Journal
  17. 17
  18. 18
    Academic Journal
  19. 19
    Academic Journal
  20. 20